VX-880 for Type 1 Diabetes

Recruiting in Palo Alto (17 mi)

+1 other location

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Vertex Pharmaceuticals Incorporated

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.

Eligibility Criteria

This trial is for people with Type 1 Diabetes who have had a kidney transplant. Participants must have been insulin-dependent for at least 5 years, be on a stable immunosuppression regimen for at least 4 weeks, and consistently use a continuous glucose monitor (CGM) for the same duration.

Inclusion Criteria

Key

I have been dependent on insulin for 5 years or more due to Type 1 Diabetes.

I've been on a steady dose of specific immunosuppressants for over 4 weeks.

+1 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive VX-880 to evaluate efficacy, safety, and tolerability

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 weeks

Participant Groups

The study tests VX-880's effectiveness, safety, and tolerability in individuals with Type 1 Diabetes who also had a kidney transplant. It aims to see how well VX-880 works as a biological/vaccine intervention in this specific patient group.

1Treatment groups

Experimental Treatment

Group I: VX-880Experimental Treatment1 Intervention